{"success":true,"data":{"pressRelease":{"id":"66307","rtpr_id":"nPreymXk7a","ticker":"AFXG","exchange":"XETRA","all_tickers":["AFXG"],"title":"ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units","author":"PR Newswire","published_at":"2026-06-17T12:00:03.263Z","article_body":"ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement\nfor 25 VISUMAX 800 Units\nPR Newswire\n\nJENA, Germany, June 17, 2026\n\nJENA, Germany, June 17, 2026 /PRNewswire/ -- ZEISS Medical Technology\nannounced today that the company held a signing ceremony with the Aier Eye\nHospital Group, entering into a strategic agreement for the purchase and\ninstallation of 25 ZEISS VISUMAX 800 femtosecond lasers across multiple Aier\nEye Hospital locations. The signing ceremony was conducted on June 12 at the\nheadquarters of Aier Eye Hospital Group in Changsha, Hunan Province.\n\n\n\nThe 25 ZEISS VISUMAX 800 systems covered by this agreement will be\nprogressively deployed across Aier Eye Hospital's domestic and international\nnetworks starting later in 2026. The strategic partnership between ZEISS\nMedical Technology and Aier Eye Hospital Group aims to enhance high-quality\npatient care through technological innovation, helping to bring precise and\nwell proven refractive surgery to patients worldwide.\n\n\"Aier Eye Hospital is one of ZEISS Medical Technology's most important global\nstrategic partners. In the future, the two parties will explore deeper\ncollaborative innovation in areas such as international expansion, integrated\ndigital workflows and platforms, and AI-assisted diagnosis,\" said Martin\nFischer, President & CEO of ZEISS Greater China.\n\n\"Our collaboration with ZEISS has long transcended mere equipment procurement.\nWe are jointly exploring comprehensive synergies spanning from clinical\nmanagement to digital applications. The introduction of 25 ZEISS VISUMAX 800\nsystems will help Aier further enhance surgical efficiency and patient\nsatisfaction, aiming to set a new quality benchmark for refractive surgery\nworldwide,\" said Mr. Li LI, Co-Founder and Global President of Aier Eye\nHospital Group.\n\nSupporting a global patient care strategy\n\nAt the signing ceremony, ZEISS Medical Technology presented Aier Eye Hospital\nGroup with a \"Top Three\" honorary plaque, acknowledging Aier's global\nleadership across three dimensions—equipment scale, talent pool, and\nclinical practice— further deepening its strategic partnership with ZEISS\nMedical Technology, including:\n1. Most ZEISS VISUMAX 800 Units Installed Globally: Aier Eye Hospital will be\nthe ophthalmic institution with the largest installed base of ZEISS VISUMAX\n800 systems worldwide;\n2. Most ZEISS SMILE pro-Certified Surgeons Globally: Aier Eye Hospital boasts\nthe largest number of ZEISS SMILE pro-certified surgeons globally,\ndemonstrating its strong advantages in technical training and talent\ndevelopment;\n3. Highest Number of Procedures with ZEISS SMILE pro in China: Aier Eye\nHospital ranks first nationwide in the total number of KLEx procedures\nperformed with ZEISS SMILE pro in China, maintaining a well-established\nposition in clinical experience and patient satisfaction.\nNot all products, services or offers are approved or offered in every market\nand approved labeling and instructions may vary from one country to another.\nFor country-specific product information, see the appropriate country website.\nProduct specifications are subject to change in design and scope of delivery\nas a result of ongoing technical development. The statements of the healthcare\nprofessionals reflect only their personal opinions and experiences and do not\nnecessarily reflect the opinion of any institution that they are affiliated\nwith. The healthcare professionals alone are responsible for the content of\ntheir experience reported and any potential resulting infringements. Carl\nZeiss Meditec AG and its affiliates to not have clinical evidence supporting\nthe opinions and statements of the health care professionals nor accept any\nresponsibility or liability of the healthcare professionals' content. The\nhealthcare professionals have a contractual or other financial relationship\nwith Carl Zeiss Meditec AG and its affiliates and have received financial\nsupport.\n\nCompany Profile\n\nCarl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and\nSDAX of the German stock exchange, is one of the world's leading medical\ntechnology companies. The Company supplies innovative technologies and\napplication-oriented solutions designed to help doctors improve the quality of\nlife of their patients. The Company offers complete solutions, including\nimplants and consumables, to diagnose and treat eye diseases. The Company\ncreates innovative visualization solutions in the field of microsurgery. With\n5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal\nyear 2024/25 (to 30 September).\n\nThe Group's head office is located in Jena, Germany, and it has subsidiaries\nin Germany and abroad; more than 50 percent of its employees are based in the\nUSA, Japan, Spain and France. The Center for Application and Research (CARIn)\nin Bangalore, India and the Carl Zeiss Innovations Center for Research and\nDevelopment in Shanghai, China, strengthen the Company's presence in these\nrapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's\nshares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of\nthe world's leading groups in the optical and optoelectronic industries.\n\nFor further information visit: www.zeiss.com/med\n\n\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/zeiss-medical-technology-and-aier-eye-hospital-group-sign-strategic-agreement-for-25-visumax-800-units-302803006.html\n\n\n\nContact for investors Sebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: investors.med@zeiss.com Contact for the press Frank SmithHead of Global Communications Ophthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331 Mail: press.med@zeiss.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1867796/Signing_for_25_units_of_VISUMAX_800-1.jpg?id=OA2722234\nhttps://mmx.prnewswire.com/media/MS780231/ZEISS_v1_Logo.jpg?id=OA2722235\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPreymXk7a","title":"ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units","author":"PR Newswire","ticker":"AFXG","created":"2026-06-17T12:00:03.263Z","tickers":["AFXG"],"exchange":"XETRA","article_body":"ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement\nfor 25 VISUMAX 800 Units\nPR Newswire\n\nJENA, Germany, June 17, 2026\n\nJENA, Germany, June 17, 2026 /PRNewswire/ -- ZEISS Medical Technology\nannounced today that the company held a signing ceremony with the Aier Eye\nHospital Group, entering into a strategic agreement for the purchase and\ninstallation of 25 ZEISS VISUMAX 800 femtosecond lasers across multiple Aier\nEye Hospital locations. The signing ceremony was conducted on June 12 at the\nheadquarters of Aier Eye Hospital Group in Changsha, Hunan Province.\n\n\n\nThe 25 ZEISS VISUMAX 800 systems covered by this agreement will be\nprogressively deployed across Aier Eye Hospital's domestic and international\nnetworks starting later in 2026. The strategic partnership between ZEISS\nMedical Technology and Aier Eye Hospital Group aims to enhance high-quality\npatient care through technological innovation, helping to bring precise and\nwell proven refractive surgery to patients worldwide.\n\n\"Aier Eye Hospital is one of ZEISS Medical Technology's most important global\nstrategic partners. In the future, the two parties will explore deeper\ncollaborative innovation in areas such as international expansion, integrated\ndigital workflows and platforms, and AI-assisted diagnosis,\" said Martin\nFischer, President & CEO of ZEISS Greater China.\n\n\"Our collaboration with ZEISS has long transcended mere equipment procurement.\nWe are jointly exploring comprehensive synergies spanning from clinical\nmanagement to digital applications. The introduction of 25 ZEISS VISUMAX 800\nsystems will help Aier further enhance surgical efficiency and patient\nsatisfaction, aiming to set a new quality benchmark for refractive surgery\nworldwide,\" said Mr. Li LI, Co-Founder and Global President of Aier Eye\nHospital Group.\n\nSupporting a global patient care strategy\n\nAt the signing ceremony, ZEISS Medical Technology presented Aier Eye Hospital\nGroup with a \"Top Three\" honorary plaque, acknowledging Aier's global\nleadership across three dimensions—equipment scale, talent pool, and\nclinical practice— further deepening its strategic partnership with ZEISS\nMedical Technology, including:\n1. Most ZEISS VISUMAX 800 Units Installed Globally: Aier Eye Hospital will be\nthe ophthalmic institution with the largest installed base of ZEISS VISUMAX\n800 systems worldwide;\n2. Most ZEISS SMILE pro-Certified Surgeons Globally: Aier Eye Hospital boasts\nthe largest number of ZEISS SMILE pro-certified surgeons globally,\ndemonstrating its strong advantages in technical training and talent\ndevelopment;\n3. Highest Number of Procedures with ZEISS SMILE pro in China: Aier Eye\nHospital ranks first nationwide in the total number of KLEx procedures\nperformed with ZEISS SMILE pro in China, maintaining a well-established\nposition in clinical experience and patient satisfaction.\nNot all products, services or offers are approved or offered in every market\nand approved labeling and instructions may vary from one country to another.\nFor country-specific product information, see the appropriate country website.\nProduct specifications are subject to change in design and scope of delivery\nas a result of ongoing technical development. The statements of the healthcare\nprofessionals reflect only their personal opinions and experiences and do not\nnecessarily reflect the opinion of any institution that they are affiliated\nwith. The healthcare professionals alone are responsible for the content of\ntheir experience reported and any potential resulting infringements. Carl\nZeiss Meditec AG and its affiliates to not have clinical evidence supporting\nthe opinions and statements of the health care professionals nor accept any\nresponsibility or liability of the healthcare professionals' content. The\nhealthcare professionals have a contractual or other financial relationship\nwith Carl Zeiss Meditec AG and its affiliates and have received financial\nsupport.\n\nCompany Profile\n\nCarl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and\nSDAX of the German stock exchange, is one of the world's leading medical\ntechnology companies. The Company supplies innovative technologies and\napplication-oriented solutions designed to help doctors improve the quality of\nlife of their patients. The Company offers complete solutions, including\nimplants and consumables, to diagnose and treat eye diseases. The Company\ncreates innovative visualization solutions in the field of microsurgery. With\n5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal\nyear 2024/25 (to 30 September).\n\nThe Group's head office is located in Jena, Germany, and it has subsidiaries\nin Germany and abroad; more than 50 percent of its employees are based in the\nUSA, Japan, Spain and France. The Center for Application and Research (CARIn)\nin Bangalore, India and the Carl Zeiss Innovations Center for Research and\nDevelopment in Shanghai, China, strengthen the Company's presence in these\nrapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's\nshares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of\nthe world's leading groups in the optical and optoelectronic industries.\n\nFor further information visit: www.zeiss.com/med\n\n\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/zeiss-medical-technology-and-aier-eye-hospital-group-sign-strategic-agreement-for-25-visumax-800-units-302803006.html\n\n\n\nContact for investors Sebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: investors.med@zeiss.com Contact for the press Frank SmithHead of Global Communications Ophthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331 Mail: press.med@zeiss.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1867796/Signing_for_25_units_of_VISUMAX_800-1.jpg?id=OA2722234\nhttps://mmx.prnewswire.com/media/MS780231/ZEISS_v1_Logo.jpg?id=OA2722235\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-17T12:00:03.321108722Z","server_sent_at_ms":1781697603321},"received_at":"2026-06-17T12:00:03.434Z","source_url":null},"analysis":{"id":"55724","press_release_id":"66307","analysis_json":{"industry":null,"redFlags":[],"eventType":"other","narrative":"ZEISS Medical Technology announced a strategic agreement with Aier Eye Hospital Group for the purchase of 25 VISUMAX 800 femtosecond lasers to be deployed across Aier's network starting in 2026.\n\nThe partnership aims to enhance patient care through technological innovation and explore further collaboration in international expansion and AI-assisted diagnosis.\n\nThe input ticker AFXG is not mentioned in the article; the disclosed information pertains exclusively to ZEISS and Aier Eye Hospital Group.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Ticker mismatch detected: Article covers ZEISS/Aier deal, but input ticker AFXG is unmentioned."},"keyFigures":{"customDimensions":{"zeiss_employees":5784,"visumax_800_units":25,"zeiss_fy_2024_25_revenue_eur_m":2228}},"quotedText":"Aier Eye Hospital is one of ZEISS Medical Technology's most important global strategic partners.","namedEntities":{"people":[{"name":"Martin Fischer","role":"President & CEO of ZEISS Greater China"},{"name":"Li LI","role":"Co-Founder and Global President of Aier Eye Hospital Group"}],"products":["ZEISS VISUMAX 800","ZEISS SMILE pro"],"companies":[{"name":"ZEISS Medical Technology","relationship":"issuer"},{"name":"Carl Zeiss Meditec AG","relationship":"parent company"},{"name":"Aier Eye Hospital Group","relationship":"partner"}],"dollarAmounts":[{"amount":"€2,228m","context":"Carl Zeiss Meditec AG revenue for fiscal year 2024/25"}]},"materialImpact":{"score":1,"reasoning":"The press release describes a strategic agreement between ZEISS Medical Technology and Aier Eye Hospital Group. The input ticker AFXG is not mentioned in the text, indicating no direct material impact on the filer."},"tickerRelevance":{"others":[],"primary":"AFXG"},"globalImportance":20,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"issuerTier":"mid-cap","eventGravity":"contract_win","tickerMismatch":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ZEISS Medical Technology announced a strategic agreement with Aier Eye Hospital Group for the purchase of 25 VISUMAX 800 femtosecond lasers to be deployed across Aier's network starting in 2026.\n\nThe partnership aims to enhance patient care through technological innovation and explore further collaboration in international expansion and AI-assisted diagnosis.\n\nThe input ticker AFXG is not mentioned in the article; the disclosed information pertains exclusively to ZEISS and Aier Eye Hospital Group.","key_figures":{"customDimensions":{"zeiss_employees":5784,"visumax_800_units":25,"zeiss_fy_2024_25_revenue_eur_m":2228}},"named_entities":{"people":[{"name":"Martin Fischer","role":"President & CEO of ZEISS Greater China"},{"name":"Li LI","role":"Co-Founder and Global President of Aier Eye Hospital Group"}],"products":["ZEISS VISUMAX 800","ZEISS SMILE pro"],"companies":[{"name":"ZEISS Medical Technology","relationship":"issuer"},{"name":"Carl Zeiss Meditec AG","relationship":"parent company"},{"name":"Aier Eye Hospital Group","relationship":"partner"}],"dollarAmounts":[{"amount":"€2,228m","context":"Carl Zeiss Meditec AG revenue for fiscal year 2024/25"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-17T12:25:46.712Z","global_importance":20,"audience_relevance":10,"importance_components":{"issuerTier":"mid-cap","eventGravity":"contract_win","tickerMismatch":true}},"durationMs":210346,"modelName":"george-droid-qwen-72b"}}